ResMed FY2026 10-K: Full-Year Revenue Up 10%, MatrixCare Sale for $490M, Astral Recall Costs $42M
RMD sits 26% above its 52-week low of $180.265.
Summary
ResMed filed its FY2026 10-K showing 10% revenue growth to $5.65B and net income of $1.52B. The filing details the $490M MatrixCare sale, $335M Noctrix acquisition, and $41.9M Astral recall costs.
Key Events · Earnings and Guidance · RMD
-
FY2026 Revenue Up 10%
Net revenue increased to $5,653M from $5,146M, driven by 10% growth in Sleep and Breathing Health and 5% in Residential Care Software.
-
MatrixCare Divestiture
A definitive agreement has been reached to sell MatrixCare for $490M in cash, with closing expected in Q1 FY2027. The business contributed $220M in revenue and $28M in operating profit during FY2026.
-
Noctrix Acquisition
The acquisition of Noctrix Health for $335M was completed on June 1, 2026, expanding the company's presence in restless legs syndrome treatment.
-
Astral Recall Costs
Field safety notification expenses of $41.9M were recognized in connection with the Astral device component replacement, impacting gross margin.
Analysis · RMD · Industrial Applications And Services
The annual report confirms robust full-year growth, with revenue up 10% to $5.65B and net income up 9% to $1.52B. It also details the $490M MatrixCare divestiture, the $335M Noctrix acquisition, and $41.9M in Astral field safety notification expenses. Together, these items establish a comprehensive financial baseline and clarify the impact of recent strategic moves and product issues.
At the time of this filing, RMD was trading at $226.74 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $32.9B. The 52-week trading range was $180.27 to $293.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.